New Trio de Kligman

The New Trio is a combination cream developed as an alternative to Kligman's Trio (KT) for treating melasma. According to the search results, this new formulation replaces hydroquinone (found in the original Kligman's Trio) with isobutylamido-thiazolyl-resorcinol (also referred to as thiamidol in some sources), while maintaining retinoic acid and corticosteroid components[1][2][5]. ## Efficacy and Clinical Performance The New Trio combination cream has demonstrated significant efficacy in treating melasma. In a 24-week monocentric trial that was randomized, double-blind, and controlled versus Kligman's Trio, the New Trio showed: - A 63% improvement in modified Melasma Area and Severity Index (mMASI) scores at week 12, compared to 39% with Kligman's Trio[2] - A mean mMASI reduction of 4.33 points (SE 0.71, p < 0.0001) after 12 weeks of treatment[5] - A substantial improvement in quality of life, with MelasQoL scores improving by -12.57 (SE 3.29, p = 0.0006)[5] ## Advantages Over Traditional Kligman's Trio The New Trio appears to offer several benefits compared to the original Kligman's Trio: 1. Better tolerance profile - the replacement of hydroquinone with thiamidol (isobutylamido-thiazolyl-resorcinol) addresses concerns about hydroquinone's poor tolerance and numerous side effects[6] 2. Greater quality of life improvement for patients[2] 3. Comparable or potentially superior efficacy to the original formulation, which has been considered the gold standard for melasma treatment since 1974[2] ## Safety Profile The tolerance of the New Trio was reported as "globally good" with no major adverse events related to the treatment throughout the study period[2]. This is particularly noteworthy as the original Kligman's Trio, while effective, has been associated with frequent adverse effects[5]. The New Trio combination appears to be an effective treatment option for melasma and could be considered as a well-tolerated alternative to the traditional Kligman's Trio formulation[5].

Other names

New Trio